IRIDEX (NASDAQ:IRIX) Releases Earnings Results, Beats Estimates By $0.01 EPS

IRIDEX (NASDAQ:IRIX) issued its quarterly earnings data on Thursday. The medical equipment provider reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.01, FiscalAI reports. IRIDEX had a negative net margin of 8.42% and a negative return on equity of 1,204.74%. The firm had revenue of $14.72 million for the quarter, compared to the consensus estimate of $14.74 million.

Here are the key takeaways from IRIDEX’s conference call:

• IRIDEX delivered a transformed financial profile in 2025 with $52.7M revenue (+8% YoY), a 22% reduction in operating expenses, positive adjusted EBITDA for the year, and positive operating cash flow in Q4.
• Commercial momentum accelerated—Cyclo G6 probe sales rose to 57,800 for the year (15,900 in Q4), PASCAL retina sales and surgical-retina exceeded plan, and AAO trade-show follow-ups have converted to nearly $1M in orders.
• Gross margin pressure is a near-term headwind—Q4 gross margin fell to 37% from 44% YoY due to higher manufacturing costs, tariff impacts and inventory write-downs.
• Management is pursuing cost actions to restore margins and free cash flow, including starting a multi-year transition to third‑party contract manufacturing in 2026 (full implementation in 2027) and relocations that are expected to yield roughly $165k quarterly and ~$600k annualized in savings.
• 2026 guidance of $51M–$53M excludes Middle East sales (about 5% of revenue) and management provided inconsistent pro‑forma growth statements, creating modeling uncertainty tied to regional disruption.

IRIDEX Trading Down 26.7%

NASDAQ IRIX opened at $0.99 on Friday. The company has a fifty day simple moving average of $1.40 and a two-hundred day simple moving average of $1.20. The stock has a market cap of $17.02 million, a P/E ratio of -3.81 and a beta of 0.67. IRIDEX has a 12-month low of $0.79 and a 12-month high of $1.65. The company has a current ratio of 1.94, a quick ratio of 1.35 and a debt-to-equity ratio of 62.29.

Hedge Funds Weigh In On IRIDEX

Hedge funds have recently made changes to their positions in the company. Jane Street Group LLC raised its stake in IRIDEX by 93.9% in the 4th quarter. Jane Street Group LLC now owns 31,758 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 15,377 shares during the last quarter. Apexium Financial LP grew its stake in IRIDEX by 53.0% during the 3rd quarter. Apexium Financial LP now owns 100,529 shares of the medical equipment provider’s stock valued at $116,000 after purchasing an additional 34,834 shares during the last quarter. Susquehanna International Group LLP increased its holdings in shares of IRIDEX by 46.2% in the third quarter. Susquehanna International Group LLP now owns 56,470 shares of the medical equipment provider’s stock valued at $65,000 after purchasing an additional 17,834 shares during the period. Finally, Citadel Advisors LLC increased its holdings in shares of IRIDEX by 62.7% in the third quarter. Citadel Advisors LLC now owns 109,473 shares of the medical equipment provider’s stock valued at $126,000 after purchasing an additional 42,202 shares during the period. 20.10% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IRIX has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of IRIDEX in a report on Monday, December 29th. Alliance Global Partners began coverage on IRIDEX in a research report on Thursday, February 5th. They issued a “buy” rating for the company. Finally, iA Financial set a $3.00 target price on IRIDEX in a research note on Thursday, February 5th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, IRIDEX presently has an average rating of “Hold” and an average price target of $3.00.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) is a medical technology company specializing in the development, manufacturing and commercialization of innovative ophthalmic laser and imaging systems. The company’s offerings focus on energy-based therapies designed to treat retinal vascular disorders, glaucoma and other ocular conditions. IRIDEX’s portfolio includes laser photocoagulation platforms, micro-pulse laser technology, and related consumable devices for use by ophthalmologists and retina specialists.

The company’s flagship products include the Cyclo G6 Glaucoma Laser System, which delivers precise, controlled micro-pulse laser therapy for patients with refractory glaucoma, and the IQ 532 Retina Laser System, designed to support minimally invasive laser treatments for diabetic retinopathy and age-related macular degeneration.